文献速递临床试验与 GCP

比较3%地夸磷索与0.1%透明质酸治疗糖尿病干眼症临床疗效的单中心随机对照试验方案

A protocol for a single center, randomized, controlled trial comparing the clinical efficacy of 3% diquafosol and 0.1% hyaluronic acid in diabetic patients with dry eye disease.
PubMed 文献 · Trials · 2023-12-12

该单中心、三盲、随机对照试验计划纳入202例糖尿病相关干眼症患者,随机分为3%地夸磷索组(n=101)和0.1%透明质酸组(n=101),每日6次、每次1滴,治疗8周。主要评估泪膜脂质层、非侵入性泪膜破裂时间、结膜角膜染色评分、角膜敏感性、泪液MMP-9水平、睑板腺表达与质量、泪河高度、角膜神经、免疫/炎症细胞变化、结膜充血及眼表疾病指数问卷评分,在基线、第4周和第8周进行比较。

要点

  • 纳入202例糖尿病相关干眼症患者,随机分为3%地夸磷索组(n=101)和0.1%透明质酸组(n=101)。
  • 两组均每日6次、每次1滴,治疗8周,在基线、第4周和第8周评估多项眼表指标。
  • 该试验为单中心、三盲、随机对照设计,旨在评估两种滴眼液的治疗效果与安全性。

核心结论

  • 该研究将是一项标准化的科学临床试验,旨在评估3%地夸磷索和0.1%透明质酸治疗糖尿病干眼症的治疗效果与安全性。

研究设计与样本

  • 单中心、三盲、随机对照试验,计划纳入202例糖尿病相关干眼症患者,随机分为3%地夸磷索组(n=101)和0.1%透明质酸组(n=101)。
  • 干预为每日6次、每次1滴,治疗8周,在基线、第4周和第8周评估多项指标。
  • 试验注册于ClinicalTrials.gov,注册号NCT05682547,注册日期2022年12月5日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The global prevalence of diabetes mellitus (DM) continues to rise and 70% of diabetic individuals have dry eye disease (DED) that leads to subsequent abnormalities of the corneal epithelium, corneal nerves, tear film, or corneal endothelium. In addition, persons with diabetes produce fewer tear secretions than healthy individuals. While several anti-inflammatory drug-based therapies for dry eye in diabetic individuals are currently being administered, their efficacy has not been studied in detail. Therefore, the aim of this study was to compare the effectiveness of 3% diquafosol (DQS) vs 0.1% hyaluronic acid (HA) eye drops in diabetic dry eye patients. METHODS: This triple-blind randomized, control trial will include 202 diabetic-related DED and will be assigned to DQS (n = 101) and HA (n = 101) one drop, six times per day for 8 weeks. Tear film lipid layer, non-invasive breakup time, conjunctivocorneal staining score, corneal sensitivity, tear MMP-9 levels, meibomian gland expression and quality, tear meniscus height, corneal nerves, immune/inflammatory cell change, conjunctival hyperemia, and ocular surface disease index questionnaire score will be assessed and compared at baseline, week 4, and week 8. DISCUSSION: This study will be a standardized, scientific, clinical trial designed to evaluate the therapeutic effects and safety of DQS and HA for diabetic dry eye treatment. TRIAL REGISTRATION: ClinicalTrials.govNCT05682547. Registered on December 05, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen J, Chen Y, Qin G, et al. A protocol for a single center, randomized, controlled trial comparing the clinical efficacy of 3% diquafosol and 0.1% hyaluronic acid in diabetic patients with dry eye disease. Trials. 2023. PMID: 38087329. doi:10.1186/s13063-023-07818-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。